Abstract
Background
Very few previous studies have examined the relationship between thyroid cancer risk and intake of phytoestrogens (PEs); furthermore, these studies have reached inconsistent results.
Methods
We analyzed data from a population-based case-control study in Connecticut in 2010–2011 including 387 histologically-confirmed thyroid cancer cases and 433 population-based controls, with compound data available concerning specific PEs. Multivariate unconditional logistic regression models were used to estimate the associations between specific PEs and the risk of thyroid cancer, adjusting for potential confounders.
Results
An elevated risk of thyroid cancer was associated with moderate to high levels of coumestrol intake (OR = 2.48, 95% CI: 1.39–4.43 for 40–80 μg/day; OR = 2.41, 95% CI: 1.32–4.40 for 80–130 μg/day; and OR = 2.38, 95% CI: 1.26–4.50 for > 200 μg/day compared to < 40 μg/day), and the main elevation in risk appeared among microcarcinomas (≤ 1 cm). A decreased risk of papillary macrocarcinomas (> 1 cm; OR = 0.26, 95% CI: 0.08–0.85 for 1860–3110 μg/day compared to < 760 μg/day) was associated with moderate genistein intake among women.
Conclusions
Our study suggests that high coumestrol intake increases the risk of thyroid cancer, especially microcarcinomas, while moderate amounts of genistein intake appear to be protective for females with thyroid macrocarcinomas.
Impact
The study highlights the importance of distinguishing between microcarcinomas and macrocarcinomas in future research on the etiology of thyroid cancer.
Keywords: thyroid cancer, phytoestrogens, case-control study, tumor size, microcarcinomas
Introduction
Over the past few decades, the age-adjusted incidence rate of thyroid cancer has been rapidly increasing worldwide (1). Compared to all other cancer types, the age-adjusted incidence rate of thyroid cancer has increased the fastest, from 8.74/100,000 in women and 3.38/100,000 in men in 1994 to 21.43/100,000 in women and 7.371/100,000 in men in 2015 (https://seer.cancer.gov/archive/csr/1975_2015/). It is now the fifth most common cancer among women in the United States (2). While improvements in diagnostic technology such as fine needle aspiration with ultrasound guidance may be associated with increased detection of microcarcinomas (diameter ≤ 1 cm), the incidences of both smaller-size tumors and larger-size tumors are increasing (1,3,4). Furthermore, studies have shown that approximately fifty percent of the variability in thyroid cancer incidence rates in the United States could not be explained by the theory of “over-diagnosis” (5,6). Established risk factors for thyroid cancer include female gender, radiation exposure to the head and neck, high body mass index (BMI), history of benign thyroid diseases, and family history of thyroid cancer (7–10). It has been suggested that nutritional factors are associated with the development of thyroid cancer (11,12). However, research on the effects of consuming foods rich in phytoestrogens (PEs) has been controversial (7,8,13–18).
PEs include isoflavonoids (genistein, daidzein, and glycitein), lignans, and coumestans (including coumestrol). Dietary PEs mostly come from beans, soy products, and foods with added soy protein or soy flour (19). Previous studies have indicated that PE-rich diets may be associated with a decreased risk of breast cancer and prostate cancer (12,20–24). As endocrine-disrupting compounds (EDCs), PEs could also potentially affect thyroid cancer risk by affecting synthesis of thyroid hormones (TH), altering thyroid stimulating hormone (TSH) levels (25), and interacting with estrogen receptors (ERs) (24,26–28).
After the Food and Drug Administration (FDA) declared that PEs have a protective effect against coronary heart disease in 1999, the sale of soy foods (only those marketed as soy products, not including foods with added soy flour and/or protein) expanded from $1 billion in 1996 to $4.5 billion in 2009 (12). Therefore, the possible influence of soy foods and their major component PEs on thyroid cancer risk warrants further investigation.
Methods
The study population has been described elsewhere (29–34). In brief, cases were histologically-confirmed thyroid cancer patients (ICD-O-3: 8021, 8050, 8052, 8130, 8260, 8290, 8330–8332, 8335, 8340–8346, 8450, 8452, 8510) in Connecticut diagnosed between 2010 and 2011. Subjects eligible for the study were aged between 21 and 84 years at diagnosis, alive at the time of interview, and had no prior cancer diagnoses, except for non-melanoma skin cancer. Cases were identified through the Yale Cancer Center’s Rapid Case Ascertainment Shared Resource (RCA). A total of 701 eligible thyroid cancer cases were identified during the study period with 462 (65.9%) completing in-person interviews. Population-based controls with Connecticut addresses were recruited using a random digit dialing method based on both cell phone and landline numbers. A total of 498 subjects participated in the study, with a participation rate of 61.5%. Cases and controls were frequency matched by age (≤ 5 years apart). Distributions of age, gender, and race were similar between the participants and non-participants for both cases and controls.
All procedures were performed following a protocol approved by the Human Investigations Committee at Yale and the Connecticut Department of Public Health. Eligible participants were reached by letter and then by phone once approved by the hospitals and by each subject’s physician (for cancer cases), or following selection through random sampling (for the control population). After obtaining written consent, eligible participants were interviewed by trained interviewers and a food frequency questionnaire (FFQ) was administered to determine their diverse diets. The frequency and amount of consumption of previously-validated PE-rich food were captured (35). These include: soy-based foods (including tofu, soy burgers or soy meat-substitutes, soymilk, bean soup, and beans), foods with added soy flour (including doughnuts, sweet rolls, Danish, pop-tarts, white bread, pancakes, waffles and French toast), as well as foods with added soy protein (including canned tuna). Additionally, a standardized, structured questionnaire was used to obtain information on major known or suspected risk factors that might confound the association between PE-rich food intake and risk of thyroid cancer. Specific PE amounts were calculated by using Diet*Calc Analysis Software version 1.5.0, which generates nutrient estimates based on the FFQ. The six compounds examined represent two major PE types found in foods: the isoflavones: genistein, daidzein, biochanin A, formononetin, and glycitein; and the coumestan: coumestrol.
Unconditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (95% CI). All cut-points of each PE subtype and of PE-rich food intake were based on the distribution among controls. We also restricted our analyses to papillary and well-differentiated thyroid cancer subtypes (the papillary and follicular subtypes were combined due to the small sample size of follicular carcinoma). In order to exam the effects of PEs on tumor size, analyses were conducted by dividing the cases into two groups according to the tumor size (microcarcinomas ≤ 1 cm, macrocarcinomas > 1 cm) among papillary carcinomas. We also analyzed thyroid cancer among women because the number of men was too small for a meaningful analysis.
After excluding participants who did not respond to the FFQ, 387 cases (83.8%) and 433 controls (86.9%) were included in the final analysis. Age, gender, race, family history of cancer of any kind, education, BMI, previous benign thyroid diseases, history of radiation exposure, previous alcohol consumption, smoking history, daily caloric intake, percentage of calories from fat, total carotenoid intake, vitamin C intake, vitamin E intake, and fiber intake were considered as potential confounding variables. Among female subjects, additional controlled confounders included age at menarche, use of oral contraceptives, age at first full-term pregnancy, menopausal status, and estrogen use. Decisions on which covariates to include in the final model were based on a greater than 10% change in the estimates. Tests for linear trends were calculated by using each individual PE variable as continuous variables in the multivariate unconditional logistic regression models. Statistical analyses for this study were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Results were considered statistically significant when 2-sided p-values were <0.05.
Results
As illustrated in Table 1, cases tended to be less educated and had a higher BMI when compared to controls. Cases were more likely to have prior benign thyroid diseases and less likely to consume alcohol. Cases were also more likely to be female compared to controls. Distributions of race, family history of cancer of any kind, smoking, previous radiation exposure, daily caloric intake, percentage of calories from fat, vitamin C intake, Vitamin E intake, and fiber intake were similar between cases and controls. The baseline characteristics of those who had available PE data were similar to the overall study population.
Table 1.
Selected characteristics among thyroid cancer cases and controls.
| Cases (n=387)a |
Controls (n=433)a |
p-value | |||
|---|---|---|---|---|---|
| # | % | # | % | ||
| Age (years) | <0.01 | ||||
| Mean (SD) | 51.7 (12.3) | 54.8 (12.5) | |||
| <40 | 68 | 17.6 | 48 | 11.1 | |
| 40- | 93 | 24.0 | 108 | 24.9 | |
| 50- | 125 | 32.3 | 121 | 27.9 | |
| 60- | 74 | 19.1 | 93 | 21.5 | |
| ≥ 70 | 27 | 7.0 | 63 | 14.6 | |
| Gender | <0.01 | ||||
| Female | 317 | 81.9 | 306 | 70.7 | |
| Male | 70 | 18.1 | 127 | 29.3 | |
| Race | 0.51 | ||||
| White | 348 | 89.9 | 394 | 91.2 | |
| Black | 16 | 4.1 | 20 | 4.6 | |
| Other | 23 | 5.9 | 18 | 4.2 | |
| BMI (kg/m2) | <0.01 | ||||
| <25 | 126 | 32.6 | 176 | 40.7 | |
| 25–29.99 | 116 | 30.0 | 146 | 33.7 | |
| ≥30 | 143 | 37.0 | 106 | 24.5 | |
| Education | <0.01 | ||||
| High school or less | 107 | 27.7 | 73 | 16.9 | |
| Some college | 24 | 6.2 | 23 | 5.3 | |
| College graduate or more | 243 | 62.8 | 323 | 74.6 | |
| Others | 12 | 3.1 | 11 | 2.5 | |
| Family history of any cancer | 0.33 | ||||
| None | 112 | 28.9 | 139 | 32.1 | |
| Any cancer | 275 | 71.1 | 294 | 67.9 | |
| Prior benign thyroid diseaseb | <0.01 | ||||
| Yes | 227 | 58.7 | 14 | 3.2 | |
| No | 160 | 41.3 | 419 | 96.8 | |
| Previous radiation exposurec | 0.63 | ||||
| Yes | 385 | 99.7 | 427 | 99.5 | |
| No | 1 | 0.3 | 2 | 0.5 | |
| Alcohol consumptiond | <0.01 | ||||
| Never | 223 | 57.6 | 193 | 44.3 | |
| Ever | 163 | 42.1 | 238 | 55.2 | |
| Smokinge | 0.54 | ||||
| Never | 270 | 70.0 | 293 | 68.0 | |
| Ever | 116 | 30.0 | 138 | 32.0 | |
| Daily caloric intake (kcal/day) | 2399 ± 1823 | 2475 ± 966 | 0.45 | ||
| % of calories from fat | 36% ± 6% | 35% ± 5% | 0.12 | ||
| Total carotenoid intake (mcg/day)f | 7338 ± 9229 | 9098 ± 12750 | 0.03 | ||
| Vitamin C intake (mg/day)f | 305 ± 313 | 321 ± 273 | 0.45 | ||
| Vitamin E intake (mg/day)f | 45 ± 99 | 42 ± 87 | 0.67 | ||
| Fiber intake (g/day) | 24 ± 20 | 26 ± 13 | 0.24 | ||
Numbers may not sum to total due to missing data.
Benign thyroid diseases included hyperthyroidism, hypothyroidism, goiter, thyroid nodules, and thyroid adenoma.
Previous radiation exposure included previous diagnostic and therapeutic radiation exposure.
Ever alcohol consumption was defined as ever had more than 12 drinks of alcoholic beverages, such as beer, wine, or liquor. 1 drink beer = 1can or bottle; 1 drink wine = 14 oz. glass; 1 drunk liquor = 1 shot.
Ever smoking was defined as ever smoked a total of 100 cigarettes or more.
Both food sources and supplements.
Compared to those whose consumption of coumestrol was less than 40 μg/day (Table 2), individuals who consumed 40–80 μg/day (OR = 2.48, 95% CI: 1.39–4.43), 80–130 μg/day (OR = 2.41, 95% CI: 1.32–4.40), or > 200 μg/day (OR = 2.38, 95% CI: 1.26–4.50) experienced an increased risk of thyroid cancer, although the linear trend was not statistically significant (p for linear trend = 0.25). Other specific PEs, total isoflavones, and total PEs were not statistically significantly associated with thyroid cancer risk. Similar patterns were noticed for papillary and well-differentiated carcinomas. No significant associations between intake of soy-based foods, foods with added soy flour, and foods with added soy protein and thyroid cancer risk were observed (Supplementary Tables S1–5).
Table 2.
Risk of thyroid cancer associated with phytoestrogen intake among all cases and by histology subtypes.
| Phytoestrogen Intake | Controls (n=433) | All cases (n=387) | Papillary (n=328) | Well differentiated (n=377) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| # | Cases | ORa | 95% CI | Cases | ORa | 95% CI | Cases | ORa | 95% CI | |
| Genistein (μg/day) | ||||||||||
| <760 | 88 | 81 | 1.00 | - | 70 | 1.00 | - | 78 | 1.00 | - |
| 760–1260 | 85 | 66 | 0.93 | (0.51, 1.68) | 55 | 0.73 | (0.39, 1.37) | 66 | 0.95 | (0.52, 1.72) |
| 1260–1860 | 86 | 74 | 1.06 | (0.60, 1.88) | 66 | 1.09 | (0.61, 1.96) | 73 | 1.10 | (0.62, 1.94) |
| 1860–3110 | 87 | 83 | 0.97 | (0.54, 1.71) | 69 | 0.74 | (0.40, 1.36) | 80 | 0.93 | (0.52, 1.67) |
| >3110 | 87 | 83 | 1.21 | (0.69, 2.12) | 68 | 0.98 | (0.54, 1.76) | 80 | 1.18 | (0.67, 2.07) |
| P for linear trend | 0.25 | 0.44 | 0.31 | |||||||
| Daidzein (μg/day) | ||||||||||
| < 530 | 88 | 73 | 1.00 | - | 62 | 1.00 | - | 70 | 1.00 | - |
| 530–910 | 85 | 72 | 1.31 | (0.72, 2.36) | 62 | 1.08 | (0.58, 2.01) | 72 | 1.35 | (0.74, 2.45) |
| 910–1310 | 86 | 76 | 1.30 | (0.73, 2.32) | 69 | 1.35 | (0.75, 2.43) | 75 | 1.34 | (0.75, 2.40) |
| 1310–2240 | 87 | 86 | 1.26 | (0.70, 2.24) | 71 | 0.98 | (0.53, 1.81) | 82 | 1.20 | (0.67, 2.16) |
| >2240 | 87 | 80 | 1.35 | (0.76, 2.39) | 64 | 1.12 | (0.61, 2.05) | 78 | 1.35 | (0.75, 2.41) |
| P for linear trend | 0.26 | 0.45 | 0.32 | |||||||
| Biochanin A (μg/day) | ||||||||||
| <30 | 108 | 136 | 1.00 | - | 105 | 1.00 | - | 126 | 1.00 | - |
| 30–50 | 81 | 70 | 0.74 | (0.43, 1.27) | 63 | 0.78 | (0.44, 1.37) | 70 | 0.81 | (0.47, 1.39) |
| 50–70 | 77 | 62 | 0.79 | (0.45, 1.36) | 53 | 0.84 | (0.47, 1.50) | 62 | 0.86 | (0.49, 1.49) |
| 70–120 | 91 | 67 | 0.70 | (0.41, 1.21) | 61 | 0.83 | (0.47, 1.47) | 67 | 0.76 | (0.44, 1.32) |
| >120 | 76 | 52 | 0.60 | (0.33, 1.08) | 46 | 0.67 | (0.36, 1.25) | 52 | 0.64 | (0.35, 1.15) |
| P for linear trend | 0.64 | 0.97 | 0.74 | |||||||
| Formononetin (μg/day) | ||||||||||
| 0 | 93 | 101 | 1.00 | - | 82 | 1.00 | - | 96 | 1.00 | - |
| 0–10 | 153 | 133 | 1.05 | (0.64, 1.71) | 118 | 1.21 | (0.72, 2.02) | 129 | 1.09 | (0.66, 1.79) |
| 10–20 | 81 | 50 | 0.80 | (0.44, 1.43) | 39 | 0.87 | (0.46, 1.63) | 50 | 0.85 | (0.47, 1.54) |
| 20–30 | 27 | 33 | 0.87 | (0.39, 1.92) | 30 | 1.11 | (0.49, 2.51) | 33 | 0.93 | (0.42, 2.06) |
| >30 | 79 | 70 | 0.98 | (0.55, 1.73) | 59 | 1.02 | (0.56, 1.89) | 69 | 1.00 | (0.56, 1.79) |
| P for linear trend | 0.79 | 0.77 | 0.85 | |||||||
| Glycitein (μg/day) | ||||||||||
| <100 | 94 | 82 | 1.00 | - | 69 | 1.00 | - | 79 | 1.00 | - |
| 100–170 | 81 | 69 | 1.34 | (0.75, 2.39) | 59 | 1.22 | (0.66, 2.25) | 69 | 1.40 | (0.78, 2.50) |
| 170–260 | 89 | 78 | 1.21 | (0.69, 2.14) | 69 | 1.20 | (0.67, 2.16) | 77 | 1.24 | (0.70, 2.20) |
| 260–430 | 86 | 76 | 1.07 | (0.60, 1.92) | 64 | 0.93 | (0.50, 1.72) | 73 | 1.05 | (0.58, 1.89) |
| >430 | 83 | 82 | 1.45 | (0.83, 2.53) | 67 | 1.26 | (0.70, 2.28) | 79 | 1.41 | (0.80, 2.48) |
| P for linear trend | 0.26 | 0.45 | 0.33 | |||||||
| Total Isoflavones (μg/day) | ||||||||||
| <1410 | 88 | 81 | 1.00 | - | 69 | 1.00 | - | 78 | 1.00 | - |
| 1410–2240 | 85 | 62 | 0.90 | (0.50, 1.64) | 53 | 0.71 | (0.38, 1.34) | 62 | 0.92 | (0.50, 1.68) |
| 2240–3280 | 89 | 82 | 1.16 | (0.66, 2.03) | 74 | 1.21 | (0.68, 2.14) | 81 | 1.19 | (0.68, 2.09) |
| 3280–5440 | 84 | 79 | 1.00 | (0.56, 1.80) | 65 | 0.76 | (0.41, 1.42) | 76 | 0.97 | (0.54, 1.75) |
| >5440 | 87 | 83 | 1.25 | (0.72, 2.18) | 67 | 1.01 | (0.56, 1.83) | 80 | 1.21 | (0.69, 2.13) |
| P for linear trend | 0.25 | 0.44 | 0.31 | |||||||
| Coumestrol (μg/day) | ||||||||||
| <40 | 94 | 76 | 1.00 | - | 63 | 1.00 | - | 71 | 1.00 | - |
| 40–80 | 85 | 117 | 2.48 | (1.39, 4.43) | 103 | 2.80 | (1.51, 5.19) | 115 | 2.53 | (1.41, 4.57) |
| 80–130 | 88 | 74 | 2.41 | (1.32, 4.40) | 59 | 2.50 | (1.31, 4.78) | 73 | 2.49 | (1.35, 4.59) |
| 130–200 | 88 | 54 | 1.45 | (0.77, 2.73) | 48 | 1.60 | (0.82, 3.14) | 54 | 1.53 | (0.81, 2.91) |
| >200 | 78 | 66 | 2.38 | (1.26, 4.50) | 55 | 2.56 | (1.30, 5.06) | 64 | 2.43 | (1.27, 4.65) |
| P for linear trend | 0.25 | 0.18 | 0.26 | |||||||
| Total Phytoestrogens (μg/day) | ||||||||||
| <1510 | 87 | 81 | 1.00 | - | 69 | 1.00 | - | 78 | 1.00 | - |
| 1510–2470 | 86 | 77 | 1.15 | (0.64, 2.05) | 67 | 0.97 | (0.53, 1.77) | 77 | 1.19 | (0.66, 2.13) |
| 2470–3400 | 86 | 65 | 1.18 | (0.67, 2.10) | 57 | 1.21 | (0.67, 2.19) | 64 | 1.22 | (0.68, 2.18) |
| 3400–5560 | 87 | 79 | 0.94 | (0.52, 1.70) | 66 | 0.74 | (0.40, 1.39) | 76 | 0.92 | (0.50, 1.66) |
| >5560 | 87 | 85 | 1.36 | (0.78, 2.37) | 69 | 1.13 | (0.63, 2.04) | 82 | 1.32 | (0.75, 2.33) |
| P for linear trend | 0.25 | 0.44 | 0.31 | |||||||
Adjusted for age, gender, race, family history of any cancer, education, BMI, history of benign thyroid disease, and previous alcohol consumption.
After stratification by tumor size (Table 3), statistically significant associations with coumestrol intake were mainly observed for microcarcinomas (OR = 4.33, 95% CI: 1.86–10.07 for 40–80 μg/day; OR = 4.38, 95% CI: 1.79–10.71 for 80–130 μg/day; and OR = 3.11, 95% CI: 1.22–7.91 for >200 μg/day compared to <40 μg/day) (p for linear trend = 0.34). Individuals who consumed 40–80 μg/day also showed an increased risk of macrocarcinomas (OR = 2.31, 95% CI: 1.09–4.86).
Table 3.
Risk of thyroid cancer associated with phytoestrogen intake for thyroid cancer among papillary carcinomas by tumor size.
| Phytoestrogen Intake | Controls (n=433) | Papillary carcinoma |
|||||
|---|---|---|---|---|---|---|---|
| ≤ 1 cm (n=158) |
> 1 cm (n=167) |
||||||
| Cases | ORa | 95% CI | Cases | ORa | 95% CI | ||
| Genistein (μg/day) | |||||||
| <760 | 88 | 37 | 1.00 | - | 31 | 1.00 | - |
| 760–1260 | 85 | 25 | 0.54 | (0.24, 1.24) | 30 | 0.86 | (0.39, 1.91) |
| 1260–1860 | 86 | 33 | 1.12 | (0.55, 2.30) | 33 | 1.06 | (0.49, 2.29) |
| 1860–3110 | 87 | 34 | 0.61 | (0.28, 1.33) | 34 | 0.75 | (0.34, 1.68) |
| >3110 | 87 | 29 | 0.78 | (0.36, 1.67) | 39 | 1.19 | (0.56, 2.53) |
| P for linear trend | 0.71 | 0.15 | |||||
| Daidzein (μg/day) | |||||||
| < 530 | 88 | 32 | 1.00 | - | 28 | 1.00 | - |
| 530–910 | 85 | 31 | 0.93 | (0.42, 2.05) | 31 | 1.07 | (0.48, 2.42) |
| 910–1310 | 86 | 33 | 1.38 | (0.66, 2.87) | 36 | 1.39 | (0.65, 3.00) |
| 1310–2240 | 87 | 35 | 0.84 | (0.39, 1.82) | 35 | 0.87 | (0.39, 1.96) |
| >2240 | 87 | 27 | 0.88 | (0.40, 1.94) | 37 | 1.34 | (0.61, 2.92) |
| P for linear trend | 0.70 | 0.15 | |||||
| Biochanin A (μg/day) | |||||||
| <30 | 108 | 49 | 1.00 | - | 55 | 1.00 | - |
| 30–50 | 81 | 37 | 1.04 | (0.51, 2.12) | 26 | 0.67 | (0.32, 1.41) |
| 50–70 | 77 | 25 | 0.90 | (0.42, 1.92) | 27 | 0.84 | (0.40, 1.76) |
| 70–120 | 91 | 30 | 1.00 | (0.49, 2.07) | 31 | 0.65 | (0.31, 1.37) |
| >120 | 76 | 17 | 0.60 | (0.25, 1.41) | 28 | 0.68 | (0.32, 1.49) |
| P for linear trend | 0.61 | 0.34 | |||||
| Formononetin (μg/day) | |||||||
| 0 | 93 | 41 | 1.00 | - | 41 | 1.00 | - |
| 0–10 | 153 | 54 | 1.11 | (0.57, 2.16) | 63 | 1.13 | (0.59, 2.16) |
| 10–20 | 81 | 22 | 0.89 | (0.41, 1.97) | 17 | 0.74 | (0.32, 1.72) |
| 20–30 | 27 | 15 | 1.22 | (0.44, 3.36) | 14 | 0.96 | (0.34, 2.72) |
| >30 | 79 | 26 | 0.97 | (0.45, 2.11) | 32 | 1.05 | (0.48, 2.28) |
| P for linear trend | 0.76 | 0.59 | |||||
| Glycitein (μg/day) | |||||||
| <100 | 94 | 36 | 1.00 | - | 32 | 1.00 | - |
| 100–170 | 81 | 31 | 1.34 | (0.63, 2.87) | 27 | 1.10 | (0.48, 2.50) |
| 170–260 | 89 | 33 | 1.14 | (0.54, 2.39) | 36 | 1.30 | (0.61, 2.74) |
| 260–430 | 86 | 33 | 0.92 | (0.42, 2.00) | 31 | 0.87 | (0.38, 1.96) |
| >430 | 83 | 25 | 1.01 | (0.46, 2.20) | 41 | 1.54 | (0.73, 3.25) |
| P for linear trend | 0.69 | 0.15 | |||||
| Total Isoflavones (μg/day) | |||||||
| <1410 | 88 | 36 | 1.00 | - | 31 | 1.00 | - |
| 1410–2240 | 85 | 24 | 0.69 | (0.31, 1.55) | 29 | 0.64 | (0.28, 1.45) |
| 2240–3280 | 89 | 37 | 1.25 | (0.61, 2.57) | 37 | 1.15 | (0.54, 2.43) |
| 3280–5440 | 84 | 33 | 0.73 | (0.33, 1.61) | 31 | 0.65 | (0.29, 1.48) |
| >5440 | 87 | 28 | 0.86 | (0.40, 1.87) | 39 | 1.13 | (0.53, 2.38) |
| P for linear trend | 0.70 | 0.15 | |||||
| Coumestrol (μg/day) | |||||||
| <40 | 94 | 24 | 1.00 | - | 39 | 1.00 | - |
| 40–80 | 85 | 56 | 4.33 | (1.86, 10.07) | 47 | 2.31 | (1.09, 4.86) |
| 80–130 | 88 | 31 | 4.38 | (1.79, 10.71) | 27 | 1.46 | (0.64, 3.30) |
| 130–200 | 88 | 23 | 2.29 | (0.91, 5.78) | 24 | 1.32 | (0.57, 3.08) |
| >200 | 78 | 24 | 3.11 | (1.22, 7.91) | 30 | 2.17 | (0.94, 5.02) |
| P for linear trend | 0.34 | 0.50 | |||||
| Total Phytoestrogens (μg/day) | |||||||
| <1510 | 87 | 36 | 1.00 | - | 31 | 1.00 | - |
| 1510–2470 | 86 | 31 | 0.88 | (0.40, 1.92) | 36 | 1.09 | (0.50, 2.37) |
| 2470–3400 | 86 | 30 | 1.32 | (0.63, 2.76) | 27 | 1.18 | (0.54, 2.59) |
| 3400–5560 | 87 | 31 | 0.63 | (0.28, 1.42) | 34 | 0.72 | (0.32, 1.65) |
| >5560 | 87 | 30 | 1.00 | (0.46, 2.15) | 39 | 1.30 | (0.61, 2.77) |
| P for linear trend | 0.71 | 0.15 | |||||
Adjusted for age, gender, race, family history of any cancer, education, BMI, history of benign thyroid disease, and previous alcohol consumption.
When the analyses were restricted to females (Table 4), a statistically significant increase in risk was only seen among those who had a coumestrol intake of 40–80 μg/day (OR = 2.08, 95% CI: 1.01–4.29) compared with those who had an intake of less than 40 μg/day. Similar patterns were observed for well-differentiated and papillary thyroid cancers (Supplementary Table S6). After stratification by tumor size (Table 5), an increased risk of papillary microcarcinomas was observed among those with a coumestrol intake of 40–80 μg/day (OR = 2.94, 95% CI: 1.12–7.73) and a decreased risk of papillary thyroid cancers with tumor size > 1cm (OR = 0.26, 95% CI: 0.08–0.85) among those with a genistein intake of 1860–3110 μg/day.
Table 4.
Risk of thyroid cancer associated with phytoestrogen intake among female subjects.
| Phytoestrogen Intake | Controls (n=306) |
Cases (n=317) |
ORa | 95% CI |
|---|---|---|---|---|
| # | # | |||
| Genistein (μg/day) | ||||
| <760 | 64 | 71 | 1.00 | - |
| 760–1260 | 62 | 55 | 0.59 | (0.28, 1.23) |
| 1260–1860 | 66 | 63 | 0.95 | (0.48, 1.90) |
| 1860–3110 | 55 | 65 | 0.88 | (0.43, 1.81) |
| >3110 | 59 | 63 | 0.82 | (0.40, 1.68) |
| P for linear trend | 0.37 | |||
| Daidzein (μg/day) | ||||
| < 530 | 65 | 64 | 1.00 | - |
| 530–910 | 60 | 60 | 1.09 | (0.53, 2.25) |
| 910–1310 | 64 | 62 | 1.36 | (0.67, 2.77) |
| 1310–2240 | 58 | 71 | 1.16 | (0.57, 2.35) |
| >2240 | 59 | 60 | 1.03 | (0.50, 2.12) |
| P for linear trend | 0.38 | |||
| Biochanin A (μg/day) | ||||
| <30 | 86 | 123 | 1.00 | - |
| 30–50 | 62 | 59 | 0.68 | (0.34, 1.35) |
| 50–70 | 59 | 52 | 0.71 | (0.35, 1.43) |
| 70–120 | 57 | 52 | 0.59 | (0.29, 1.21) |
| >120 | 42 | 31 | 0.56 | (0.27, 1.28) |
| P for linear trend | 0.82 | |||
| Formononetin (μg/day) | ||||
| 0 | 61 | 82 | 1.00 | - |
| 0–10 | 101 | 106 | 1.09 | (0.57, 2.07) |
| 10–20 | 62 | 43 | 0.77 | (0.37, 1.58) |
| 20–30 | 20 | 29 | 0.62 | (0.22, 1.75) |
| >30 | 62 | 57 | 0.82 | (0.39, 1.72) |
| P for linear trend | 0.38 | |||
| Glycitein (μg/day) | ||||
| <100 | 68 | 71 | 1.00 | - |
| 100–170 | 62 | 60 | 0.89 | (0.44, 1.79) |
| 170–260 | 66 | 66 | 1.17 | (0.58, 2.35) |
| 260–430 | 52 | 60 | 0.96 | (0.46, 2.01) |
| >430 | 58 | 60 | 0.94 | (0.46, 1.89) |
| P for linear trend | 0.42 | |||
| Total Isoflavones (μg/day) | ||||
| <1410 | 65 | 70 | 1.00 | - |
| 1410–2240 | 63 | 53 | 0.74 | (0.36, 1.52) |
| 2240–3280 | 66 | 68 | 1.15 | (0.57, 2.30) |
| 3280–5440 | 54 | 63 | 1.01 | (0.49, 2.09) |
| >5440 | 58 | 63 | 0.94 | (0.46, 1.92) |
| P for linear trend | 0.37 | |||
| Coumestrol (μg/day) | ||||
| <40 | 67 | 65 | 1.00 | - |
| 40–80 | 62 | 104 | 2.08 | (1.01, 4.29) |
| 80–130 | 60 | 59 | 1.56 | (0.73, 3.35) |
| 130–200 | 68 | 48 | 1.35 | (0.63, 2.88) |
| >200 | 49 | 41 | 1.50 | (0.64, 3.54) |
| P for linear trend | 0.94 | |||
| Total Phytoestrogens (μg/day) | ||||
| <1510 | 63 | 69 | 1.00 | - |
| 1510–2470 | 65 | 67 | 0.94 | (0.47, 1.91) |
| 2470–3400 | 64 | 54 | 1.21 | (0.59, 2.49) |
| 3400–5560 | 56 | 63 | 0.89 | (0.42, 1.87) |
| >5560 | 58 | 64 | 1.04 | (0.51, 2.12) |
| P for linear trend | 0.37 | |||
Adjusted for age, race, family history of any cancer, education, BMI, history of benign thyroid disease, age at menarche, use of oral contraceptives, age at first full-term pregnancy, menopausal status, estrogen use and previous alcohol consumption.
Table 5.
Risk of thyroid cancer associated with phytoestrogen intake for thyroid cancer among papillary carcinomas by tumor size among female subjects.
| Phytoestrogen Intake | Controls (n=306) | Papillary carcinoma |
|||||
|---|---|---|---|---|---|---|---|
| ≤ 1 cm (n=142) |
> 1 cm (n=126) |
||||||
| Cases | ORa | 95% CI | Cases | ORa | 95% CI | ||
| Genistein (μg/day) | |||||||
| <760 | 64 | 33 | 1.00 | - | 28 | 1.00 | - |
| 760–1260 | 62 | 24 | 0.40 | (0.15, 1.07) | 23 | 0.34 | (0.12, 0.98) |
| 1260–1860 | 66 | 32 | 1.19 | (0.51, 2.75) | 26 | 0.54 | (0.19, 1.51) |
| 1860–3110 | 55 | 27 | 0.60 | (0.24, 1.53) | 25 | 0.26 | (0.08, 0.85) |
| >3110 | 59 | 26 | 0.48 | (0.18, 1.26) | 24 | 0.53 | (0.19, 1.49) |
| P for linear trend | 0.60 | 0.31 | |||||
| Daidzein (μg/day) | |||||||
| < 530 | 65 | 29 | 1.00 | - | 25 | 1.00 | - |
| 530–910 | 60 | 29 | 0.77 | (0.30, 1.97) | 24 | 0.85 | (0.30, 2.42) |
| 910–1310 | 64 | 31 | 1.80 | (0.76, 4.27) | 27 | 0.94 | (0.33, 2.64) |
| 1310–2240 | 58 | 28 | 0.67 | (0.26, 1.74) | 27 | 0.42 | (0.13, 1.33) |
| >2240 | 59 | 25 | 0.63 | (0.24, 1.69) | 23 | 0.84 | (0.29, 2.39) |
| P for linear trend | 0.60 | 0.31 | |||||
| Biochanin A (μg/day) | |||||||
| <30 | 86 | 48 | 1.00 | - | 46 | 1.00 | - |
| 30–50 | 62 | 35 | 0.77 | (0.33, 1.83) | 20 | 0.86 | (0.32, 2.32) |
| 50–70 | 59 | 22 | 0.79 | (0.32, 1.95) | 22 | 0.81 | (0.29, 2.25) |
| 70–120 | 57 | 27 | 0.79 | (0.33, 1.89) | 21 | 0.41 | (0.14, 1.25) |
| >120 | 42 | 10 | 0.38 | (0.12, 1.18) | 17 | 0.91 | (0.30, 2.71) |
| P for linear trend | 0.59 | 0.63 | |||||
| Formononetin (μg/day) | |||||||
| 0 | 61 | 40 | 1.00 | - | 29 | 1.00 | - |
| 0–10 | 101 | 49 | 1.28 | (0.57, 2.86) | 45 | 0.87 | (0.34, 2.24) |
| 10–20 | 62 | 19 | 0.77 | (0.30, 1.93) | 15 | 0.74 | (0.25, 2.19) |
| 20–30 | 20 | 13 | 0.86 | (0.24, 3.04) | 12 | 0.57 | (0.13, 2.47) |
| >30 | 62 | 21 | 0.59 | (0.22, 1.59) | 25 | 0.76 | (0.26, 2.19) |
| P for linear trend | 0.26 | 0.50 | |||||
| Glycitein (μg/day) | |||||||
| <100 | 68 | 32 | 1.00 | - | 28 | 1.00 | - |
| 100–170 | 62 | 30 | 1.05 | (0.43, 2.55) | 23 | 0.56 | (0.20, 1.60) |
| 170–260 | 66 | 31 | 1.31 | (0.55, 3.11) | 28 | 0.79 | (0.29, 2.16) |
| 260–430 | 52 | 26 | 0.83 | (0.32, 2.17) | 23 | 0.44 | (0.14, 1.40) |
| >430 | 58 | 23 | 0.66 | (0.25, 1.73) | 24 | 0.68 | (0.25, 1.88) |
| P for linear trend | 0.54 | 0.35 | |||||
| Total Isoflavones (μg/day) | |||||||
| <1410 | 65 | 32 | 1.00 | - | 28 | 1.00 | - |
| 1410–2240 | 63 | 23 | 0.62 | (0.24, 1.62) | 23 | 0.32 | (0.11, 0.95) |
| 2240–3280 | 66 | 36 | 1.53 | (0.66, 3.57) | 27 | 0.66 | (0.24, 1.83) |
| 3280–5440 | 54 | 25 | 0.75 | (0.29, 1.92) | 24 | 0.25 | (0.07, 0.83) |
| >5440 | 58 | 26 | 0.61 | (0.23, 1.59) | 24 | 0.56 | (0.20, 1.58) |
| P for linear trend | 0.60 | 0.31 | |||||
| Coumestrol (μg/day) | |||||||
| <40 | 67 | 22 | 1.00 | - | 32 | 1.00 | - |
| 40–80 | 62 | 55 | 2.94 | (1.12, 7.73) | 38 | 2.16 | (0.80, 5.86) |
| 80–130 | 60 | 29 | 2.55 | (0.91, 7.14) | 18 | 0.65 | (0.19, 2.20) |
| 130–200 | 68 | 21 | 1.57 | (0.56, 4.38) | 22 | 1.28 | (0.43, 3.79) |
| >200 | 49 | 15 | 1.41 | (0.44, 4.56) | 16 | 1.02 | (0.29, 3.68) |
| P for linear trend | 0.93 | 0.41 | |||||
| Total Phytoestrogens (μg/day) | |||||||
| <1510 | 63 | 32 | 1.00 | - | 27 | 1.00 | - |
| 1510–2470 | 65 | 30 | 0.85 | (0.34, 2.13) | 30 | 0.65 | (0.24, 1.78) |
| 2470–3400 | 64 | 29 | 1.60 | (0.66, 3.85) | 19 | 0.72 | (0.25, 2.12) |
| 3400–5560 | 56 | 24 | 0.64 | (0.24, 1.70) | 26 | 0.27 | (0.08, 0.91) |
| >5560 | 58 | 27 | 0.72 | (0.28, 1.88) | 24 | 0.69 | (0.24, 1.97) |
| P for linear trend | 0.60 | 0.31 | |||||
Adjusted for age, race, family history of any cancer, education, BMI, history of benign thyroid disease, age at menarche, use of oral contraceptives, age at first full-term pregnancy, menopausal status, estrogen use and previous alcohol consumption.
Discussion
This population-based case-control study suggests that an increased risk of thyroid cancer is associated with coumestrol consumption, which is the most estrogenic PE (22). The observed associations varied by tumor size (≤ 1 cm vs > 1 cm). Our study results also suggest that moderate genistein intake is associated with a decreased risk of thyroid cancer with larger tumor size among females.
There is only one previous study, by Horn-Ross et al. in San Francisco, that has investigated coumestrol intake and thyroid cancer risk (7). They did not find an association between coumestrol intake and thyroid cancer risk. The inconsistency could be due to the different cut-offs of coumestrol consumption. Their reference level was less than 81.3 μg/day, which contained both our reference (< 40 μg/day) and low exposure (40–80 μg/day) groups. When our analysis was performed applying the same cut-offs as the San Francisco study (<81.3, 81.4–123.1, 123.2–167.7, 167.8–270.4, ≥ 270.5 μg/day), we found no significant association between coumestrol intake and thyroid cancer risk, which is consistent with their findings. The paradoxical results could be due to the reference group in the Horn-Ross’ study incorporating that which was the exposure group (40–80 μg/day) in our study, which showed more than two-times the risk of thyroid cancer.
Coumestrol is the most estrogenic compound and has the highest receptor binding affinity to both ER-α and ER-β, followed by genistein (36). The proliferation of thyroid cancer cells is positively stimulated by ER-α agonists and inhibited by ER-β agonists (37) in particular ER-β1 (38,39). Moreover, in a prior experimental study including subjects with small well-differentiated thyroid cancers (average tumor size 9.4 mm), there was a greater expression of ER-α among tumor tissues than normal tissues (40). It has also been suggested that there are fewer ER-β1 receptors in smaller tumors (< 2 cm) compared to larger tumors (38). Therefore, it is possible that coumestrol increases microcarcinoma risk by agonizing over-expressed ER-α in smaller tumors, in addition to lessening the protective effect from ER-β, thus leading to microcarcinoma proliferation.
Notably, we did not observe a linear relationship between coumestrol intake and thyroid cancer risk. The possible explanations include: 1) some agents are carcinogenic at low-exposure levels, but their carcinogenic potential does not increase with higher exposure such as radiation to the thyroid (41); 2) a higher dose exposure could paradoxically be protective, as the mutagenic rate is overwhelmed by apoptosis; 3) the sample size in each category is insufficient to demonstrate small differences.
In addition, thyroid microcarcinomas have shown the fastest increase in incidence and approximately half of all newly-diagnosed thyroid cancers were microcarcinomas (4). An observational study of papillary microcarcinomas from Japan demonstrated that patients with papillary microcarcinomas that showed enlargement of 3 mm or more constituted 6.4% and 15.9% of patients at 5-year and 10-year follow-ups, respectively, and that the enlargement process was unrelated to patient background or clinical features (42). Thus, thyroid microcarcinoma appears to be a distinct entity with pathophysiological features that are distinct from macrocarcinomas.
The anticarcinogenic effect of genistein on thyroid cancer has been demonstrated by previous studies (24,43,44). Evidence has shown that genistein could function as an anticarcinogen due to its higher binding affinity to ER-β than to ER-α (36), thereby leading to a more anti-proliferative effect, inducing apoptosis and inhibiting angiogenesis (43,44). Although it has been suggested that increased TSH levels are associated with an increase in thyroid cancer risk by causing less differentiation and more malignant cell transformation (45–47), multiple randomized controlled trials (RCTs) have consistently shown that genistein supplementation did not change TSH levels with various doses (25,48–51), suggesting that the protective effect of genistein was not through a TSH pathway. The San Francisco study (7), though not statistically significant, showed a 30% thyroid cancer risk reduction in the highest genistein intake group (OR = 0.70; 95% CI 0.44–1.1). Among our female population, low to moderate genistein intake was associated with a 56% decrease in papillary thyroid cancer risk. When the analyses were stratified by tumor size, decreased risk was observed mainly among larger tumors. The amount of ER-α expression in macrocarcinomas is about 1.3 times the amount in microcarcinomas (52) while the binding capacity of genistein to ER-β is five to seven times higher than to ER-α (36). Therefore, it is possible that the binding capacity of ER-β overcomes the number of ER-α and thus leads to a greater anticarcinogenic effect on macrocarcinomas (40). Again, this suggests that microcarcinomas and macrocarcinomas possess different pathophysiologies.
Support for an association between total intake of isoflavones and thyroid cancer risk has been inconsistent (7,15,18). Two case-control studies have suggested that high isoflavone intake has a protective effect against thyroid cancer (7,15). One prospective cohort study (18) found no association, which is consistent with our findings. Previous RCTs have concluded that isoflavone soy protein supplements do not affect serum TSH levels (25,50,53). Therefore, it is unlikely that total isoflavone intake affects thyroid cancer risk by influencing TSH levels.
Historically, the major consumers of soy foods were Asian countries such as China, Korean and Japan (54). The estimated daily soy consumption was found to be higher in China, Korean and Japan (soy and soy foods: 23.5–135.4 g/day, 21.07 g/day, and 50.7–102.1 g/day, respectively; soy protein: 2.5–10.3 g/day, 7.4–8.5 g/day and 6–11.3 g/day, respectively) (55) than in the US with one previous study showing an average soy protein intake of 9.25 g/day, with higher consumption found among vegetarians (55,56). The concentrations of genistein and coumestrol measured in various foods differed by area and population (35,57,58). In general, the genistein mainly comes from soy-based foods (such as soybeans, soymilk, tofu, soy protein, and black bean sauce) and foods with added soy flour or protein (such as doughnuts, “power”-type bars, etc.). The main sources of coumestrol include sprouts (such as alfalfa sprouts, clover sprouts and mung bean sprouts), soy-based products (such as soybeans, soymilk and tofu) and foods with added soy flour or protein (such as canned tuna, doughnuts, pancakes and waffles). Overall, the level of genistein in the same food category is much higher than the level of coumestrol (35,57).
Previous observational studies have shown inconsistent results regarding the effects of soy-based food consumption on thyroid cancer risk, with some studies suggesting a protective effect (7,14,15) and other studies reporting no associations (8,13,18). Our study found no statistically significant relationship between soy-based food consumption and thyroid cancer risk. Studies that reported a protective effect were mainly conducted in Asian populations, (7,14,15) where soy food consumption was higher than in Western populations. This may suggest that soy-based food consumption, especially at a relatively higher amount, could be beneficial in the prevention of thyroid cancer, and genistein may play an important role in the anticarcinogenic process.
Our study, consistent with a study conducted in San Francisco, has shown no association between foods with added soy flour or protein and thyroid cancer risk (7). It has been suggested that there is a positive relationship between refined cereals and thyroid cancer (16,17). Though foods with added soy flour, such as doughnuts, pancakes, and waffles, have a relatively high genistein content, the potential anticarcinogenic effects of genistein may be cancelled out by their high sugar components, which can cause glycemic overload, elevated insulin and insulin-like growth factor level, and can subsequently promote tumor cell growth (16,59). It has been suggested that fresh fish consumption is a protective factor against thyroid cancer, but consumption of processed fish, such as canned tuna, has been linked to an increased risk of thyroid cancer (17,60). The proposed mechanism is that the additives in processed foods may affect iodine absorption and potentially cause iodine deficiency (60). Iodine deficiency is associated with increased thyroid cancer risk (61). Therefore, foods with added soy flour or protein, due to their mixed components and other possible carcinogenic factors, may promote tumor proliferation.
To the best of our knowledge, this is the first study to investigate the effects of both specific phytoestrogenic compounds and soy-based foods on thyroid cancer risk by tumor size. Our study has several strengths. Firstly, Diet*Calc Analysis Software was adopted to estimate phytoestrogen compound levels. The accurate measurement of specific nutrients could decrease the possibility of exposure misclassification. Furthermore, carefully reviewed pathologic reports allowed for stratified analysis based on the pathological information.
However, the present study also has limitations. Dietary intake was self-reported and thus might lead to potential recall bias. Because the relationship between PE intake and thyroid cancer risk has not been well-established, potential recall bias is likely to be non-differential and result in an underestimation of the true association. Due to limited sample size, the study was unable to investigate the association between phytoestrogen intake and rare histologic subtypes, such as medullary and anaplastic thyroid cancer. The subgroup analyses, which were stratified by histology, gender, and tumor size, might yield unstable results. The FFQ in our study captured the vast majority of previously validated phytoestrogen-rich food; however, certain food items, mainly Asian-style bean products and sprouts, that contain high levels of genistein (such as Chinese black bean sauce, Natto (fermented Japanese beans), and soybean sprouts) and coumestrol (such as clover sprouts, soybean sprouts, alfalfa sprouts and mung bean sprouts) were not included (https://data.nal.usda.gov/dataset/usda-database-isoflavone-content-selected-foods-release-21-november-2015/resource/1de757af). Nevertheless, according to a Centers for Disease Control and Prevention (CDC) population survey (62), among the Connecticut respondents (with 88.6% being of white race), only 3.9% of them reported consuming alfalfa sprouts, 6.0% bean sprouts and 8.7% other sprouts, which included clover sprouts. The consumption was significantly lower than in Asian countries, where sprouts have been common foods since ancient times (63). Hence, the uncaptured phytoestrogen-rich food items were unlikely to make a significant contribution to our final results. Lastly, our study did not include lignans, the quantities of which were undetected or of trace amounts in most foods (35), which could potentially result in an underestimation of total phytoestrogen exposure.
Conclusion
This population-based case-control study supports the hypothesis that coumestrol is associated with an increased risk of thyroid cancer with small tumor size and that genistein is associated with a decreased risk of thyroid cancer with larger tumor size among females. The novel finding that risks varied by tumor size warrants further investigation.
Supplementary Material
Acknowledgements
Certain data used in this study was obtained from the Connecticut Tumor Registry located in the Connecticut Department of Public Health. The authors assume full responsibility for the analyses and interpretation of this data. The cooperation of the Connecticut hospitals, including Charlotte Hungerford Hospital, Bridgeport Hospital, Danbury Hospital, Hartford Hospital, Middlesex Hospital, Hospital of Central Connecticut, Yale/New Haven Hospital, St. Francis Hospital and Medical Center, St. Mary’s Hospital, Hospital of St. Raphael, St. Vincent’s Medical Center, Stamford Hospital, William W. Backus Hospital, Windham Hospital, Eastern Connecticut Health Network, Griffin Hospital, Bristol Hospital, Johnson Memorial Hospital, Greenwich Hospital, Lawrence and Memorial Hospital, New Milford Hospital, Norwalk Hospital, MidState Medical Center, John Dempsey Hospital, and Waterbury Hospital, in allowing patient access, is gratefully acknowledged. Rajni Mehta from the Yale Comprehensive Cancer Center’s RCA provided great help in both Institutional Review Board (IRB) approvals and field implementation of the study. Helen Sayward, Anna Florczak, and Renee Capasso from the Yale School of Public Health did exceptional work in study subject recruitment.
Source of funding:
1. American Cancer Society (ACS) grant RSGM-10-038-01-CCE, recipient: Yawei Zhang
2. National Institutes of Health (NIH) grant R01ES020361, recipient: Yawei Zhang
Abbreviations
- BMI
Body Mass Index
- CDC
Centers for Disease Control and Prevention
- CI
Confidence Intervals
- EDCs
Endocrine-Disrupting Compounds
- E2
Estradiol
- ERs
Estrogen Receptors
- FFQ
Food Frequency Questionnaire
- ICD
International Classification of Diseases
- IRB
Institutional Review Board
- OR
Odds Ratio
- PEs
Phytoestrogens
- RCA
Rapid Case Ascertainment
- RCT
Randomized Controlled Trial
- TRs
Thyroid Receptors
- TSH
Thyroid Stimulating Hormone
- Tg
Thyroglobulin
Footnotes
Conflicts of interest: There are no conflicts of interest in this paper.
References
- 1.Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 2018;124(13):2785–800 doi 10.1002/cncr.31551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999–2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2018. [Google Scholar]
- 3.Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973–2004. Thyroid 2009;19(10):1061–6 doi 10.1089/thy.2008.0342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA 2017;317(13):1338–48 doi 10.1001/jama.2017.2719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013. doi 10.1089/thy.2013.0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid 2014;24(3):472–9 doi 10.1089/thy.2013.0257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Horn-Ross PL, Hoggatt KJ, Lee MM. Phytoestrogens and thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 2002;11(1):43–9. [PubMed] [Google Scholar]
- 8.Takezaki T, Hirose K, Inoue M, Hamajima N, Kuroishi T, Nakamura S, et al. Risk factors of thyroid cancer among women in Tokai, Japan. J Epidemiol 1996;6(3):140–7. [DOI] [PubMed] [Google Scholar]
- 9.Rinaldi S, Lise M, Clavel-Chapelon F, Boutron-Ruault MC, Guillas G, Overvad K, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012;131(6):E1004–14 doi 10.1002/ijc.27601. [DOI] [PubMed] [Google Scholar]
- 10.Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011;20(3):464–72 doi 10.1158/1055-9965.epi-10-1220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Greenlee H WE, Patterson RE, Kristal AR; Vitamins and Lifestyle (VITAL) Study Cohort. Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J Altern Complement Med 2004. [DOI] [PubMed] [Google Scholar]
- 12.D’Adamo CR, Sahin A. Soy foods and supplementation: a review of commonly perceived health benefits and risks. Altern Ther Health Med 2014;20 Suppl 1:39–51. [PubMed] [Google Scholar]
- 13.Przybylik-Mazurek E, Hubalewska-Dydejczyk A, Kuzniarz-Rymarz S, Kiec-Klimczak M, Skalniak A, Sowa-Staszczak A, et al. Dietary patterns as risk factors of differentiated thyroid carcinoma. Postepy Hig Med Dosw (Online) 2012;66:11–5 doi 10.5604/17322693.974647. [DOI] [PubMed] [Google Scholar]
- 14.Zhu QX, Bian JC, Shen Q, Tang HW, Zhang HW, Wu Y. [A matched case-control study of papillary thyroid carcinoma]. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27(5):416–9. [PubMed] [Google Scholar]
- 15.Haselkorn T, Stewart SL, Horn-Ross PL. Why are thyroid cancer rates so high in southeast asian women living in the United States? The bay area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 2003;12(2):144–50. [PubMed] [Google Scholar]
- 16.Chatenoud L, La Vecchia C, Franceschi S, Tavani A, Jacobs DR Jr., Parpinel MT, et al. Refined-cereal intake and risk of selected cancers in italy. Am J Clin Nutr 1999;70(6):1107–10. [DOI] [PubMed] [Google Scholar]
- 17.Braganza MZ, Potischman N, Park Y, Thompson FE, Hollenbeck AR, Kitahara CM. Adolescent and mid-life diet and subsequent risk of thyroid cancer in the NIH-AARP diet and health study. Int J Cancer 2015;137(10):2413–23 doi 10.1002/ijc.29600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Xiao Q, Park Y, Hollenbeck AR, Kitahara CM. Dietary flavonoid intake and thyroid cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2014;23(6):1102–8 doi 10.1158/1055-9965.EPI-13-1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Dixon RA. PHYTOESTROGENS. Annual Review of Plant Biology 2004;55(1):225–61 doi 10.1146/annurev.arplant.55.031903.141729. [DOI] [PubMed] [Google Scholar]
- 20.Messina M. Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature. Nutrients 2016;8(12) doi 10.3390/nu8120754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Xu MSKaX. DIETARY PHYTOESTROGENS. Annual Review of Nutrition 1997;17(1):353–81 doi 10.1146/annurev.nutr.17.1.353. [DOI] [PubMed] [Google Scholar]
- 22.Hedelin M, Löf M, Olsson M, Adlercreutz H, Sandin S, Weiderpass E. Dietary Phytoestrogens Are Not Associated with Risk of Overall Breast Cancer But Diets Rich in Coumestrol Are Inversely Associated with Risk of Estrogen Receptor and Progesterone Receptor Negative Breast Tumors in Swedish Women. The Journal of Nutrition 2008;138(5):938–45. [DOI] [PubMed] [Google Scholar]
- 23.Yin F, Giuliano AE, Van Herle AJ. Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 1999;9(4):369–76 doi 10.1089/thy.1999.9.369. [DOI] [PubMed] [Google Scholar]
- 24.Long M, Kruger T, Ghisari M, Bonefeld-Jorgensen EC. Effects of selected phytoestrogens and their mixtures on the function of the thyroid hormone and the aryl hydrocarbon receptor. Nutrition and cancer 2012;64(7):1008–19 doi 10.1080/01635581.2012.711419. [DOI] [PubMed] [Google Scholar]
- 25.Dillingham BL, McVeigh BL, Lampe JW, Duncan AM. Soy protein isolates of varied isoflavone content do not influence serum thyroid hormones in healthy young men. Thyroid 2007;17(2):131–7 doi 10.1089/thy.2006.0206. [DOI] [PubMed] [Google Scholar]
- 26.Tiosano D, Paris F, Grimaldi M, Georgescu V, Servant N, Hochberg Z, et al. Evidence of ERalpha and ERbeta selectivity and partial estrogen agonism in traditional Chinese medicine. Reprod Biol Endocrinol 2014;12:97 doi 10.1186/1477-7827-12-97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kang HJ, Youn YK, Hong MK, Kim LS. Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals. J Korean Med Sci 2011;26(7):893–9 doi 10.3346/jkms.2011.26.7.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 2006;70(4):1414–23 doi 10.1124/mol.106.026344. [DOI] [PubMed] [Google Scholar]
- 29.Zhang Y, Chen Y, Huang H, Sandler J, Dai M, Ma S, Udelsman R Diagnostic radiography exposure increases the risk for thyroid microcarcinoma: a population-based case-control study. Eur J Cancer Prev (In press) 2015. doi 10.1097/CEJ.0000000000000169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zeng F, Lerro C, Lavoue J, Huang H, Siemiatycki J, Zhao N, et al. Occupational exposure to pesticides and other biocides and risk of thyroid cancer. Occupational and environmental medicine 2017;74(7):502–10 doi 10.1136/oemed-2016-103931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Sandler JE, Huang H, Zhao N, Wu W, Liu F, Ma S, et al. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev 2018;27(3):285–94 doi 10.1158/1055-9965.Epi-17-0319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Luo J, Deziel NC, Huang H, Chen Y, Ni X, Ma S, et al. Cell phone use and risk of thyroid cancer: a population-based case-control study in Connecticut. Annals of epidemiology 2019;29:39–45 doi 10.1016/j.annepidem.2018.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Huang H, Zhao N, Chen Y, Deziel N, Dai M, Li N, et al. Alcohol Consumption and Risk of Thyroid Cancer: A Population Based Case-Control Study in Connecticut. Adv Exp Med Biol 2018;1032:1–14 doi 10.1007/978-3-319-98788-0_1. [DOI] [PubMed] [Google Scholar]
- 34.Ba Y, Huang H, Lerro CC, Li S, Zhao N, Li A, et al. Occupation and Thyroid Cancer: A Population-Based, Case-Control Study in Connecticut. Journal of occupational and environmental medicine 2016;58(3):299–305 doi 10.1097/jom.0000000000000637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Horn-Ross PL, Barnes S, Lee M, Coward L, Mandel JE, Koo J, et al. Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer causes & control : CCC 2000;11(4):289–98. [DOI] [PubMed] [Google Scholar]
- 36.Choi SY, Ha TY, Ahn JY, Kim SR, Kang KS, Hwang IK, et al. Estrogenic activities of isoflavones and flavones and their structure-activity relationships. Planta medica 2008;74(1):25–32 doi 10.1055/s-2007-993760. [DOI] [PubMed] [Google Scholar]
- 37.Magri F, Capelli V, Gaiti M, Villani L, Zerbini F, La Manna L, et al. ER-alpha and ER-beta expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation. Endocrine 2014. doi 10.1007/s12020-014-0457-x. [DOI] [PubMed] [Google Scholar]
- 38.Huang Y, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma. BMC cancer 2014;14:383- doi 10.1186/1471-2407-14-383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Dong W, Li J, Zhang H, Huang Y, He L, Wang Z, et al. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer. International journal of clinical and experimental pathology 2015;8(6):7149–56. [PMC free article] [PubMed] [Google Scholar]
- 40.Magri F, Capelli V, Rotondi M, Leporati P, La Manna L, Ruggiero R, et al. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient’s risk. Endocr Relat Cancer 2012;19(4):463–71 doi 10.1530/erc-11-0389. [DOI] [PubMed] [Google Scholar]
- 41.de Vathaire F, Haddy N, Allodji RS, Hawkins M, Guibout C, El-Fayech C, et al. Thyroid Radiation Dose and Other Risk Factors of Thyroid Carcinoma Following Childhood Cancer. The Journal of clinical endocrinology and metabolism 2015;100(11):4282–90 doi 10.1210/jc.2015-1690. [DOI] [PubMed] [Google Scholar]
- 42.Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010;34(1):28–35 doi 10.1007/s00268-009-0303-0. [DOI] [PubMed] [Google Scholar]
- 43.Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138(3):863–70 doi 10.1210/endo.138.3.4979. [DOI] [PubMed] [Google Scholar]
- 44.Jantan I, Ahmad W, Bukhari SN. Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front Plant Sci 2015;6:655 doi 10.3389/fpls.2015.00655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Huang H, Rusiecki J, Zhao N, Chen Y, Ma S, Yu H, et al. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev 2017;26(8):1209–18 doi 10.1158/1055-9965.EPI-16-0845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nature genetics 2012;44(3):319–22 doi 10.1038/ng.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Ostergaard JN, Overvad K, et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. Journal of the National Cancer Institute 2014;106(6):dju097 doi 10.1093/jnci/dju097. [DOI] [PubMed] [Google Scholar]
- 48.Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 2011;93(2):356–67 doi 10.3945/ajcn.110.008359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bitto A, Polito F, Atteritano M, Altavilla D, Mazzaferro S, Marini H, et al. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism 2010;95(6):3067–72 doi 10.1210/jc.2009-2779. [DOI] [PubMed] [Google Scholar]
- 50.Bruce B, Messina M, Spiller GA. Isoflavone supplements do not affect thyroid function in iodine-replete postmenopausal women. J Med Food 2003;6(4):309–16 doi 10.1089/109662003772519859. [DOI] [PubMed] [Google Scholar]
- 51.Ham JO, Chapman KM, Essex-Sorlie D, Bakhit RM, Prabhudesai M, Winter L, et al. Endocrinological response to soy protein and fiber in mildly hypercholesterolemic men. Nutrition Research 1993;13(8):873–84 doi 10.1016/s0271-5317(05)80590-1. [DOI] [Google Scholar]
- 52.Vannucchi G, De Leo S, Perrino M, Rossi S, Tosi D, Cirello V, et al. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. Eur J Endocrinol 2015;173(1):29–36 doi 10.1530/eje-15-0054. [DOI] [PubMed] [Google Scholar]
- 53.Persky VW, Turyk ME, Wang L, Freels S, Chatterton R Jr., Barnes S, et al. Effect of soy protein on endogenous hormones in postmenopausal women. Am J Clin Nutr 2002;75(1):145–53. [DOI] [PubMed] [Google Scholar]
- 54.Huang H, Krishnan HB, Pham Q, Yu LL, Wang TT. Soy and Gut Microbiota: Interaction and Implication for Human Health. Journal of agricultural and food chemistry 2016;64(46):8695–709 doi 10.1021/acs.jafc.6b03725. [DOI] [PubMed] [Google Scholar]
- 55.Rizzo G, Baroni L. Soy, Soy Foods and Their Role in Vegetarian Diets. Nutrients 2018;10(1):43 doi 10.3390/nu10010043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Jaceldo-Siegl K, Fraser GE, Chan J, Franke A, Sabate J. Validation of soy protein estimates from a food-frequency questionnaire with repeated 24-h recalls and isoflavonoid excretion in overnight urine in a Western population with a wide range of soy intakes. Am J Clin Nutr 2008;87(5):1422–7 doi 10.1093/ajcn/87.5.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutrition and cancer 2006;54(2):184–201 doi 10.1207/s15327914nc5402_5. [DOI] [PubMed] [Google Scholar]
- 58.Huang M-H, Norris J, Han W, Block T, Gold E, Crawford S, et al. Development of an updated phytoestrogen database for use with the SWAN food frequency questionnaire: intakes and food sources in a community-based, multiethnic cohort study. Nutrition and cancer 2012;64(2):228–44 doi 10.1080/01635581.2012.638434. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Malaguarnera R, Vella V, Nicolosi ML, Belfiore A. Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer? Frontiers in endocrinology 2017;8:314- doi 10.3389/fendo.2017.00314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Memon A, Varghese A, Suresh A. Benign thyroid disease and dietary factors in thyroid cancer: a case-control study in Kuwait. British journal of cancer 2002;86(11):1745–50 doi 10.1038/sj.bjc.6600303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res 2015;8:8 doi 10.1186/s13044-015-0020-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Centers for Disease Control and Prevention (CDC). Foodborne Active Surveillance Network (FoodNet) Population Survey Atlas of Exposures. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2006–2007. [Google Scholar]
- 63.Tang D, Dong Y, Ren H, Li L, He C. A review of phytochemistry, metabolite changes, and medicinal uses of the common food mung bean and its sprouts (Vigna radiata). Chem Cent J 2014;8(1):4- doi 10.1186/1752-153X-8-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.